伦康依隆妥单抗对比化疗治疗复发/转移性食管鳞状细胞癌患者的多中心、随机、开放、Ⅲ期临床研究（PANKU-Esophagus01）

国家1.1类创新药物千层纸素片治疗晚期恶性实体瘤患者的安全性、耐受性和剂量探索性的Ⅰb/Ⅱa期临床研究报告

芦康沙妥珠单抗（sac-TMT）一线治疗不可切除的局部晚期或转移性三阴性乳腺癌（a/m TNBC）：OptiTROP-Breast05 Ⅱ期研究的更新结果

自体肿瘤浸润淋巴细胞（GC101 TIL）在PD-1抗体耐药晚期黑色素瘤中的疗效与安全性：一项多中心、开放标签、随机对照的关键Ⅱ期临床试验（MIZAR-003）

一项比较PD-1/VEGF双特异性抗体（PF-08634404）与帕博利珠单抗联合含铂化疗方案用于局部晚期或转移性非小细胞肺癌一线治疗的Ⅲ期临床研究（Symbiotic-Lung-01）

伦康依隆妥单抗对比医师选择的化疗方案治疗不可切除局部晚期或转移性三阴性乳腺癌患者的随机、Ⅲ期临床研究（PANKU-Breast02）

Risvutatug Rezetecan对照拓扑替康治疗小细胞肺癌二线患者的Ⅲ期研究（ARTEMIS-008）主要结果

一项PD-1/VEGF双特异性抗体（PF-08634404）联合化疗一线治疗广泛期小细胞肺癌的Ⅱ/Ⅲ期临床研究（Symbiotic-Lung-04）

多模态统一生存集成模型（MUSE-i）预测三阴性乳腺癌（TNBC）免疫治疗的生存获益：来自TORCHLIGHT研究的分析

靶向Nectin-4的多肽偶联药物SC-101治疗晚期尿路上皮癌：Ⅰ期剂量递增及剂量扩展研究的更新结果

局限期小细胞肺癌大分割同步放化疗后斯鲁利单抗巩固治疗的疗效与安全性：一项全国多中心Ⅱ期临床研究（ASTRUM-LC01）

自体肿瘤浸润淋巴细胞改良疗法（GC101 TIL）在PD-1抗体耐药晚期黑色素瘤中的疗效与安全性：一项多中心、开放标签、随机对照的关键Ⅱ期临床试验（MIZAR-003）

Pembrolizumab Plus Chemotherapy in Participants From China With Advanced Esophageal Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-590 Study  

纳武利尤单抗（NIVO）联合伊匹木单抗（IPI） vs 仑伐替尼（LEN）或索拉非尼（SOR）一线治疗不可切除肝细胞癌（uHCC）：CheckMate 9DW研究中国人群4年随访以及基于肝功能的探索性分析     

Short-Course Radiotherapy-Based Total Neoadjuvant Therapy With or Without a PD-1 Inhibitor in pMMR Locally Advanced Rectal Cancer: Short-Term Results from a Randomized Phase 3 Trial (STELLAR Ⅱ)

Overall survival with first-line amivantamab plus lazertinib in advanced NSCLC harboring atypical EGFR mutations: extended follow-up from CHRYSALIS-2

皮下注射抗PD-L1单克隆抗体恩沃利单抗联合吉西他滨与奥沙利铂（GEMOX方案）对比GEMOX方案一线治疗中国晚期胆道癌患者：一项随机、开放标签、多中心Ⅲ期注册临床试验     

Atezolizumab with or without tiragolumab in patients with unresectable esophageal squamous cell carcinoma that has not progressed following definitive concurrent chemoradiotherapy: The SKYSCRAPER-07 China subpopulation analysis

德曲妥珠单抗（Trastuzumab Deruxtecan，T-DXd）在人表皮生长因子受体2（HER2）阳性不可切除或转移性胃癌（GC）或胃食管结合部腺癌（GEJA）患者中的应用：DESTINY-Gastric04研究中国亚组分析

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5-Year Follow-Up and Response Analyses From the Phase 3 EV-302 Study

放化疗后分子残留病灶（MRD）清除在局限期小细胞肺癌中的预后价值：一项前瞻性纵向研究

Tumor response and disease progression per RECIST v1.1 and mRECIST in the Phase 3 EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolization (TACE) in embolization-eligible hepatocellular carcinoma

Adjuvant Zoledronic Acid Reduces Recurrence and Improves Disease-Free Survival in Breast Malignant Phyllodes Tumors via Suppressing CREB1-PLK1: A Phase 2 Trial

Long-Term Follow-Up of the KEYNOTE-859 China Subgroup: Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Advanced or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

Multi-omics-based Immunometabolic Classification of Lung Squamous Cell Carcinoma and the Mechanism of the XBP1-WNT10A Axis Drives Myofibroblast Reprogramming to Reshape an Immunosuppressive Microenvironment

ET-SPACE Near-Infrared Whole-Body Hyperthermia Combined with Immune Checkpoint Inhibition and RTK Inhibition for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Open-Label, Randomized Controlled Trial

Alveltamig（ZG006）在2线及以上晚期神经内分泌癌患者中的 剂量优化Ⅱ期研究（ZG006-003）

NDRG1-targeted nanocarrier enhances radiofrequency ablation efficacy in hepatocellular carcinoma through ferroptosis amplification and immune remodeling